About Transcell Biosciences
Transcell Biosciences is a company based in Hyderabad (India) founded in 2009. It operates as a Managed Services and HealthTech. Transcell Biosciences has raised $2.21 million across 5 funding rounds from investors including Lemon Tree Hotels, Quantiphi and Primarc. Transcell Biosciences offers products and services including ScellCare, PREGEN, HSCT, BARTI, and TRUCB. Transcell Biosciences operates in a competitive market with competitors including StemCyte, China Cord Blood, Generate, LaCell and Forever Labs, among others.
- Headquarter Hyderabad, India
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Transcell Biolife
-
Annual Revenue
$55.72 K (USD)-37as on Mar 31, 2023
-
Net Profit
-$86.22 K (USD)-18as on Mar 31, 2023
-
EBITDA
$3.44 K (USD)-88as on Mar 31, 2023
-
Total Equity Funding
$2.21 M (USD)
in 5 rounds
-
Latest Funding Round
$1.39 M (USD), Series A
Jul 19, 2024
-
Investors
Lemon Tree Hotels
& 72 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Transcell Biosciences
Transcell Biosciences offers a comprehensive portfolio of products and services, including ScellCare, PREGEN, HSCT, BARTI, and TRUCB.
Cord blood units are collected and stored compliantly.
Predictive and advisory services are provided with registration.
Damaged bone marrow is replaced for treatment.
Natural healing is promoted with tooth implants.
Plasma yields are enhanced for industrial applications.
Transformative medicinal applications are optimized through data.
Innovative drug solutions are developed for health.
Funding Insights of Transcell Biosciences
Transcell Biosciences has successfully raised a total of $2.21M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $1.39 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series A — $1.4M
-
First Round
First Round
(07 Nov 2015)
- Investors Count 73
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2024 | Amount | Series A - Transcell Biosciences | Valuation | Quantiphi | |
| Dec, 2022 | Amount | Seed - Transcell Biosciences | Valuation | Indian Angel Network | |
| Apr, 2017 | Amount | Seed - Transcell Biosciences | Valuation |
investors |
Investors in Transcell Biosciences
Transcell Biosciences has secured backing from 73 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include Lemon Tree Hotels, Quantiphi and Primarc.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Angel investor network investing in early-stage startups
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on seed-stage investments
|
Founded Year | Domain | Location | |
|
Private investment arm of Kris Gopalakrishnan Family Office.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Transcell Biosciences
Financial Statements - Transcell Biosciences
Transcell Biosciences Comparisons
Competitors of Transcell Biosciences
Transcell Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as StemCyte, China Cord Blood, Generate, LaCell and Forever Labs, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Umbilical cord blood stem cell transplantation and therapeutic products company
|
|
| domain | founded_year | HQ Location |
Biobanking services for umbilical cord blood stem cells are provided.
|
|
| domain | founded_year | HQ Location |
Provider of services for the storage of stem cells
|
|
| domain | founded_year | HQ Location |
Stem Cell Production
|
|
| domain | founded_year | HQ Location |
Stem cells are stored and preserved for future therapeutic applications.
|
|
| domain | founded_year | HQ Location |
Stem cell biobanking and manufacturing from children's teeth are provided.
|
Frequently Asked Questions about Transcell Biosciences
Transcell Biosciences was founded in 2009 and raised its 1st funding round 6 years after it was founded.
Transcell Biosciences is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Transcell Biosciences is a funded company, having raised a total of $2.21M across 5 funding rounds to date. The company's 1st funding round was a Seed of $301.91K, raised on Nov 07, 2015.
Annual revenue of Transcell Biosciences is $55.72K as on Mar 31, 2023.
Stem cell banking and transformative medicinal applications are facilitated by Transcell Biosciences. Based in India, the company focuses on biobanking functions for personalized healthcare solutions. Services include cord blood storage, predictive advisory, stem cell transplantation, regenerative implants, plasma fractionation, population omics, and drug discovery. The healthcare sector is primarily served, with an emphasis on patient-centric and data-driven approaches. Innovative solutions are developed to address over 80 diseases through stem cell technology.
Transcell Biosciences's top competitors include StemCyte, Forever Labs and China Cord Blood.
Transcell Biosciences offers ScellCare, PREGEN, HSCT, BARTI, and 3 more products and services.
Transcell Biosciences has 73 investors. Key investors include Lemon Tree Hotels, Quantiphi, Primarc, Pidilite, and ADVIK Hi-Tech.
The valuation of Transcell Biosciences is $11.59M as of Jul 2024.